Medical network - on March 8, 2017, and there are many drugs will lose patent protection, comprehensive market intelligence agencies, public securities filings, the FDA information records, court documents and other resources, this paper selects 10 will lose patent drugs in the United States this year, the 10 drugs are varieties of large pharmaceutical companies, on the market for many years, these drugs have to have their company brings considerable income. This 10 drugs in the United States last year the combined sales of more than $100, therapeutic areas include multiple sclerosis, HIV, erectile dysfunction, cancer and other indications.
For brand drug patents expire means generic competition, heralding the brand drug sales will decline, even is a decline in the precipice type, this is undoubtedly a blow for the pharmaceutical enterprises, especially those blockbuster drugs. To make up for lost sales brand drug patents expire, some pharmaceutical companies have also taken some measures, including trying to extend the brand medicine patent period, to upgrade of product, increase the new growth point, even through layoffs to reduce the cost.
He 1, Copaxone (g)
Common name: acetic acid granite for ray
He won FDA approval in 1996. He was teva a best-selling product, according to the product sales in the United States in 2016, it is also the most heavyweight face generic competition this year varieties, and its long-term preparations also faces more worrying patent problems. G he loss of the first generation of preparation date earlier than expected, the new generation of long-acting agents release drug facing the same problem. Once a patent is lost, teva will lose billions of dollars.
On April 16, 2015, the FDA approved first he generics. The generic drugs will be by the Momenta and novartis subsidiary sandoz joint development, according to the FDA, the generic drugs in the treatment of recurrent patients with multiple sclerosis when he, can replace completely but given g he patent problem, the drug is not yet on the market.
Teva is trying to patent litigation to defend the grams of franchise, he but it won't be easy. Last year, the company lost two key patent in the patent litigation, in January, the court also ruled that the long-acting version 4 drug patent is invalid. Analysts predict that teva litigation efforts will be to no avail.
2, Cialis (Cialis)
Cialis won in 2003 the FDA approved for erectile dysfunction, in 2011 the FDA approved for benign prostatic hyperplasia. Lilly of the drug not only listed in the top 10 list, the United States patent expires in 2017 and it also will face the biggest sales slide. Evaluate Pharma analysts predict that 2022 Cialis sales in the United States will fall to $55 million, compared with $1.45 billion in sales in 2016, the decline of 96%.
Lilly in 2017 will have three best-selling product lose patent protection, Cialis is just one of them. The company is relying on layoffs and cut costs through a difficult period, the company is in the hope of the new product, such as diabetes drug Trulicity and Jardiance to reverse the unfavorable situation.
3, Viagra Viagra
Viagra is very familiar with a drug, the drug was originally as a heart disease drugs being developed, but clinical trials were found to have good effect on male erectile dysfunction. The legendary blue pill will face generic competition in the end of the year. Since 1998, approved, viagra has come a long way. This drug is a reliable sales engine, partly thanks to Pfizer ability in the international market to promote the product, in addition, the drug is perfect formula also played a promoting role for sales.
In Pfizer viagra patent really spent a lot of attention, and success will viagra market exclusive rights in the United States until 2019. But according to Pfizer and teva and Michael's agreement, after the two companies began on December 11 can sell viagra generics. Analysts predict that viagra sales next year will fall to $359 million, will be as low as $2022 in 188 million.
4, Velcade (jose carreras)
Common name: boron substitute with rice
In 2015, suffered a blow, takeda its multiple myeloma blockbuster drug Velcade a patent, which expires in 2022 by the United States federal judge ruled invalid, it's for generic competition this year to clear the obstacles. At present, takeda is ready to accept the reality and the day will soon come.
Evaluate Pharma analyst forecasts, due to generic competition, Velcade to will cost about $1 billion in sales in 2022, from $2016 in 1.13 billion fell to $2022 in 187 million. At present, teva subsidiary, carlos tevez and Fresenius has approved the generic drugs. Takeda is now hoping to subsequent oral drug Velcade Ninlaro to compensate for the Velcade suffered losses due to generic competition.
5, Sustiva
In 2016, bristol-myers squibb, for its cancer immunotherapy drugs to expose a lot of headlines. But the company also trumpeted its powerful antiviral specializes in products, including its Sustiva anti-hiv drugs, according to the company in 2016, according to securities filings this drug would lose their franchise in December.
Sustiva is a kind of nucleoside reverse transcriptase inhibitors, its work by preventing HIV multiplication, the drug in the U.S. in 2016 sales of $901 million. But a number of generic landing are waiting for the us market. Companies such as teva, Emcure, Strides, Aurobindo had temporarily approved Sustiva generics.
Sustiva compound patent expired in 2013, and the method is used to treat HIV patent expired in September next year. But other patents in dispute. Bristol-myers squibb previously won the exclusive rights in pediatrics, the drug and to extend its market exclusivity for six months. The exclusive rights to expire in November, so generic drugs can be listed in December.
Bristol-myers squibb suffered more patents, including its state o pp, the company is counting on a new brand of drugs to help compensate for the losses, which includes the company's immune worth of single tumor drug resistance, the drug has reached $3.8 billion in annual sales.
6 and Sandostatin LAR (for injection) Mr Octreotide acetate microspheres
Although novartis Sandostatin LAR will lose patent protection in early 2017, but this kind of drugs in the next few years is expected to continue to maintain a certain number of sales. Sandostatin franchise also includes a quick release product. Evaluate Pharma prediction, Sandostatin franchise sales in 2017 and 2018 will have small growth, but a slight drop in the next few years to $820 million. There are a few companies are currently seeking approval of generic drugs, generic is difficult, but the product production and development is more complex, so the market access threshold is higher.
7, Norditropin SimpleXx
Norditropin SimpleXx is novo nordisk only drugs listed in the top 10 U.S. patent expires in 2017, the product is a kind of auxin agents, in the end of the patent expires. But luckily, due to the injection and man's pen patents, so the drug in the short term is unlikely to face generic competition.
Norditropin except in the United States this year in Germany, China and Japan will lose patent protection. Novo nordisk with this product to become a global leader in the field of auxin products, Norditropin occupy 35% of the world's market share. The company introduced the product in last century 80 s.
8, Viread (tenofovir)
Viread is a new generation of gilead nucleoside analogue reverse transcriptase inhibitors in the first drug. The drug is approved for the first time in 2001, gilead and surrounding the development of several compound drugs, including advance blockbuster drugs. Now, according to the patent reconciliation agreement and gilead, teva end of this year will be able to launch its Viread generics.
Loss of Viread patents, is a worse to gilead, because the company c product sales setback. Analysts predict that Viread lose patent protection, its sales will be sharply this year, its sales to 2022 will fall to $15 million.
9 Pristiq.
Pfizer's antidepressant medication Pristiq went public in 2008, when its predecessor Effexor patents expire. Pristiq Effexor active ingredient venlafaxine is an "improved" type of drugs. Pristiq originally developed by wyeth, wyeth in 2009 by Pfizer's takeover.
Pristiq sales peaked at $737 million in 2014, fell to $2015 in 715 million, in 2016 fell to $578 million. Information according to the FDA, Michael LAN, he, carlos tevez and sandoz has approved Pristiq generics.
10, Strattera (3-phenyipropanol paxil)
In 2016, lilly Strattera has more than $500 million in sales in the United States, but the drug sales have begun to decline. By 2022, sales of the drug may be lower than any other drugs on the list. Strattera get approved by FDA for the first time in 2002. So far, Apotex, Aurobindo, sanders, Glenmark, sun pharmaceutical, Wallace and Dr. Reddy's has been temporarily approved Strattera generics.
Refer to the article: the Top 10 U.S. patent losses of 2017 |
